List your tool

Head to head · 2026

NeuroClues vs Proscia

Pricing, free plans, ratings, features, pros and cons, side by side. Where one comes out ahead, we mark it.

NeuroClues

Eye-tracking medical device that uses AI to detect early biomarkers of Parkinson's, Alzheimer's, and multiple sclerosis

4.3Not listed

Visit NeuroClues (opens NeuroClues in a new tab)

Proscia

FDA-cleared digital pathology platform for primary diagnosis and biomarker research

4.3Not listed

Visit Proscia (opens Proscia in a new tab)

Who comes out ahead

Based only on the facts in our directory. The right pick still depends on the job you need done.

  • Lower starting price

    Not comparable

    Not comparable: NeuroClues does not list a price

  • Free plan

    Tie

    Neither has one

  • Higher rating

    Tie

    4.3 against 4.3

  • Same job?

    Yes

    Both are Healthcare AI tools

Side by side

Compared onNeuroCluesProscia
Our rating4.34.3
Starts atNot listedNot listed
Free planNoNo
CategoryHealthcare AIHealthcare AI
PlansSee pricingSee pricing
Key features
  • Portable, CE-marked Class IIa medical device for clinical eye-movement recording
  • Calibration-free patient setup using dual infrared cameras at 400 fps
  • AI-derived biomarkers benchmarked against reference ranges for clinical interpretation
  • Early-detection targeting for Parkinson's, Alzheimer's, and multiple sclerosis
  • Deployment across university hospitals and private neurology practices in seven-plus countries
  • FDA-cleared for primary clinical diagnosis in AP-Dx
  • Concentriq AP, AP-Dx and LS configurations
  • Biomarker research and clinical trial workflows
  • Cloud deployment
  • Predetermined Change Control Plan for regulatory compliance
Pros
  • CE-marked Class IIa medical device status gives it real regulatory clearance, not only research-stage promise
  • More than €22 million raised, including a €10 million Series A, signals investor confidence
  • Aims at detection years before visible symptoms, where neurological treatment has the most impact
  • FDA clearance for primary diagnosis, not just research viewing
  • Deployed across 4,000 hospitals and 16 of the top 20 pharma companies
  • Rated highest in KLAS 2026 in both the US and Europe
Cons
  • No published pricing, and as a clinical device it is sold directly to institutions, not individuals
  • Limited so far to the European market and CE marking, without confirmed FDA clearance
  • As a diagnostic aid, findings still require a neurologist's clinical interpretation, not a standalone verdict
  • No published pricing
  • Requires compatible scanning hardware
  • Adoption is a laboratory-wide programme, not a purchase
CompanyneuroClues, founded 2020Proscia Inc.

Prices come from each vendor's pricing page, last checked 20260814. Check the vendor before you buy.

FAQ

Questions people ask

Is NeuroClues better than Proscia?

In our reviews NeuroClues scores 4.3 and Proscia scores 4.3. The better pick depends on the job. NeuroClues: Eye-tracking medical device that uses AI to detect early biomarkers of Parkinson's, Alzheimer's, and multiple sclerosis. Proscia: FDA-cleared digital pathology platform for primary diagnosis and biomarker research.

Which is cheaper, NeuroClues or Proscia?

NeuroClues: see pricing. Proscia: see pricing.

Do NeuroClues and Proscia have free plans?

Neither lists a free plan.

More comparisons

NeuroClues compared with

All NeuroClues alternatives

Proscia compared with

All Proscia alternatives